Table 1 Demographics and clinical data of the intention-to-treat (ITT) population [13]
From: Frovatriptan and Rizatriptan Economic EVAluation: the FREEVA study
ITT (N = 125) | |
|---|---|
Age (years, mean ± SD) | 37 ± 9 |
Females (n, %) | 99 (79) |
Height (cm, mean ± SD) | 167 ± 9 |
Weight (kg, mean ± SD) | 64 ± 13 |
Age at onset of migraine (years, mean ± SD) | 16 ± 7 |
Migraine with aura (n, %) | 4 (3) |
MIDAS score (mean ± SD) | 22 ± 15 |
Migraine attack duration >2 days (n, %) | 26 (21) |